Clinical Trial Update: Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating gefitinib in esophageal cancer that progressed after chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Esophageal Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: University of Oxford | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | Phase 3 | Status: COMPLETED